SRPT Sarepta Therapeutics Inc
Price (delayed)
$60.53
Market cap
$5.87B
P/E Ratio
24.51
Dividend/share
N/A
EPS
$2.47
Enterprise value
$6.1B
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going
Highlights
The net income has soared by 144% YoY and by 93% QoQ
The EPS has soared by 143% YoY and by 58% from the previous quarter
Sarepta Therapeutics's quick ratio has decreased by 16% YoY but it has increased by 15% from the previous quarter
Sarepta Therapeutics's gross margin has decreased by 5% YoY and by 3.1% from the previous quarter
Key stats
What are the main financial stats of SRPT
Market
Valuations
Earnings
Shares outstanding
97.03M
Market cap
$5.87B
Enterprise value
$6.1B
Price to earnings (P/E)
24.51
Price to book (P/B)
3.78
Price to sales (P/S)
3.03
EV/EBIT
23.39
EV/EBITDA
19.39
EV/Sales
3.21
Revenue
$1.9B
Gross profit
$1.58B
Operating income
$218.08M
Net income
$235.24M
EBIT
$260.77M
EBITDA
$314.67M
Free cash flow
-$342.74M
Per share
Balance sheet
Liquidity
EPS
$2.47
EPS diluted
$2.34
Free cash flow per share
-$3.6
Book value per share
$15.99
Revenue per share
$20.01
TBVPS
$41.68
Total assets
$3.96B
Total liabilities
$2.44B
Debt
$1.33B
Equity
$1.53B
Working capital
$2.34B
Debt to equity
0.87
Current ratio
4.2
Quick ratio
2.67
Net debt/EBITDA
0.72
Margins
Efficiency
Dividend
EBITDA margin
16.5%
Gross margin
83.2%
Net margin
12.4%
Operating margin
11.5%
Return on assets
6.6%
Return on equity
19.7%
Return on invested capital
7%
Return on capital employed
8.1%
Return on sales
13.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SRPT stock price
How has the Sarepta Therapeutics stock price performed over time
Intraday
1.75%
1 week
12.53%
1 month
-20.7%
1 year
-51.28%
YTD
-50.22%
QTD
-5.16%
Financial performance
How have Sarepta Therapeutics's revenue and profit performed over time
Revenue
$1.9B
Gross profit
$1.58B
Operating income
$218.08M
Net income
$235.24M
Gross margin
83.2%
Net margin
12.4%
SRPT's operating income has soared by 181% year-on-year and by 169% since the previous quarter
SRPT's operating margin has soared by 153% YoY and by 135% from the previous quarter
The net income has soared by 144% YoY and by 93% QoQ
SRPT's net margin has surged by 129% year-on-year and by 68% since the previous quarter
Growth
What is Sarepta Therapeutics's growth rate over time
Valuation
What is Sarepta Therapeutics stock price valuation
P/E
24.51
P/B
3.78
P/S
3.03
EV/EBIT
23.39
EV/EBITDA
19.39
EV/Sales
3.21
The EPS has soared by 143% YoY and by 58% from the previous quarter
SRPT's P/E is 85% below its last 4 quarters average of 163.9
The company's equity has surged by 78% YoY and by 25% QoQ
SRPT's P/B is 73% below its 5-year quarterly average of 13.7 and 66% below its last 4 quarters average of 11.0
The P/S is 75% less than the 5-year quarterly average of 12.0 and 63% less than the last 4 quarters average of 8.0
The revenue has soared by 53% YoY and by 16% QoQ
Efficiency
How efficient is Sarepta Therapeutics business performance
Sarepta Therapeutics's ROIC has soared by 144% YoY and by 100% from the previous quarter
The ROA has soared by 139% YoY and by 83% from the previous quarter
The ROS has soared by 133% YoY and by 73% from the previous quarter
The return on equity has surged by 128% year-on-year and by 67% since the previous quarter
Dividends
What is SRPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SRPT.
Financial health
How did Sarepta Therapeutics financials performed over time
The total assets is 63% more than the total liabilities
The total assets has increased by 21% YoY and by 10% from the previous quarter
Sarepta Therapeutics's quick ratio has decreased by 16% YoY but it has increased by 15% from the previous quarter
SRPT's debt is 13% smaller than its equity
The company's equity has surged by 78% YoY and by 25% QoQ
The debt to equity has declined by 46% year-on-year and by 24% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.